Systematic Financial Management LP Buys 10,237 Shares of Jazz Pharmaceuticals PLC $JAZZ

Systematic Financial Management LP raised its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 2.6% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 407,114 shares of the specialty pharmaceutical company’s stock after acquiring an additional 10,237 shares during the period. Jazz Pharmaceuticals comprises about 1.8% of Systematic Financial Management LP’s investment portfolio, making the stock its 5th biggest position. Systematic Financial Management LP’s holdings in Jazz Pharmaceuticals were worth $76,965,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Sei Investments Co. boosted its stake in shares of Jazz Pharmaceuticals by 33.4% in the first quarter. Sei Investments Co. now owns 147,270 shares of the specialty pharmaceutical company’s stock worth $27,844,000 after buying an additional 36,870 shares during the last quarter. Lido Advisors LLC acquired a new stake in Jazz Pharmaceuticals during the first quarter worth about $237,000. Globeflex Capital L P raised its position in Jazz Pharmaceuticals by 130.8% during the first quarter. Globeflex Capital L P now owns 10,594 shares of the specialty pharmaceutical company’s stock valued at $2,003,000 after acquiring an additional 6,003 shares in the last quarter. State of Wyoming purchased a new position in Jazz Pharmaceuticals during the first quarter valued at approximately $417,000. Finally, First Trust Advisors LP lifted its holdings in Jazz Pharmaceuticals by 108.0% in the first quarter. First Trust Advisors LP now owns 91,302 shares of the specialty pharmaceutical company’s stock valued at $17,261,000 after acquiring an additional 47,402 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on JAZZ. Deutsche Bank Aktiengesellschaft upped their price objective on Jazz Pharmaceuticals from $250.00 to $270.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. Weiss Ratings raised shares of Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, June 29th. Bank of America boosted their target price on shares of Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. Canaccord Genuity Group started coverage on shares of Jazz Pharmaceuticals in a report on Thursday, July 16th. They set a “buy” rating and a $290.00 price target on the stock. Finally, Raymond James Financial restated an “outperform” rating and set a $239.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $259.06.

Insiders Place Their Bets

In related news, Director Heather Ann Mcsharry sold 2,000 shares of the company’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $241.00, for a total transaction of $482,000.00. Following the completion of the transaction, the director owned 18,449 shares in the company, valued at $4,446,209. This represents a 9.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Neena M. Patil sold 1,200 shares of the firm’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total transaction of $278,196.00. Following the completion of the transaction, the executive vice president directly owned 51,549 shares in the company, valued at $11,950,604.67. This represents a 2.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 13,098 shares of company stock valued at $3,131,906. 4.10% of the stock is owned by company insiders.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $254.87 on Friday. The company’s fifty day moving average price is $236.87 and its 200 day moving average price is $202.88. Jazz Pharmaceuticals PLC has a 1 year low of $105.00 and a 1 year high of $255.20. The stock has a market capitalization of $16.01 billion, a P/E ratio of -12,737.13, a P/E/G ratio of 0.22 and a beta of 0.32. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The company had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. As a group, equities research analysts anticipate that Jazz Pharmaceuticals PLC will post 21.9 earnings per share for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.